Targeting the dark side of the human genome—non-coding regulatory elements—to treat diseases
TargetNCREs aims to harness therapeutic potential of non-coding regulatory elements through innovative high-throughput screening, validating targets for commercial applications and market development.
Projectdetails
Introduction
The 98% of the human genome, sometimes referred to as the dark side of the human genome, contains many non-coding regulatory elements (NCREs). These elements control the combinational expression of the limited number of genes (only 2% of the genome) to form diverse cell types and tissues of a complex human body, all from the identical copy of the genome.
Genetic Variants and Therapeutic Targets
Most genetic variants and mutations also lie in NCREs. However, the number of NCREs as potential therapeutic targets remains very limited.
Project Overview
In TargetNCREs, two novel and unique high-throughput screening systems further developed within the ECR starting grant (Silencer) will be exploited for their innovation and commercial potential to harness the therapeutic values of NCREs.
Objectives
We aim to:
- Test and validate previously identified top hits in vivo.
- Carry out pilot research to show the technologies to be effective and appropriate for commercial applications.
- Clarify the IPR protection strategy.
- Engage partners and stakeholders to focus on potential pipelines.
- Perform a market search for future business development.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-5-2024 |
Einddatum | 31-10-2025 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- ACADEMISCH ZIEKENHUIS LEIDENpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Profile nucleases and Repurpose Off-Targets to Expand Gene EditingThe PROTÉGÉ project aims to enhance gene editing safety and diversity by profiling programmable nucleases and exploring off-target effects for improved precision in genetic therapies. | ERC Starting... | € 1.141.779 | 2023 | Details |
Targeting long non-coding RNAs for novel treatment strategies in vascular diseasesThis project aims to identify and target specific long non-coding RNAs involved in vascular diseases using innovative RNA interference strategies to improve treatment outcomes. | ERC Consolid... | € 1.999.495 | 2023 | Details |
Genetically anchored drug target discovery for neglected diseasesGenDrug aims to develop innovative algorithms integrating genomic and real-world data to identify drug targets and accelerate drug development for neglected non-communicable diseases. | ERC Starting... | € 1.498.089 | 2024 | Details |
In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain DiseasesThis project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively. | ERC Consolid... | € 2.249.895 | 2022 | Details |
Harnessing a novel CRISPR nuclease for programmable counterselection in human cellsThis project aims to enhance CRISPR genome editing efficiency by developing a programmable counter-selection mechanism to eliminate unedited cells, thereby reducing screening burdens in various applications. | ERC Proof of... | € 150.000 | 2024 | Details |
Profile nucleases and Repurpose Off-Targets to Expand Gene Editing
The PROTÉGÉ project aims to enhance gene editing safety and diversity by profiling programmable nucleases and exploring off-target effects for improved precision in genetic therapies.
Targeting long non-coding RNAs for novel treatment strategies in vascular diseases
This project aims to identify and target specific long non-coding RNAs involved in vascular diseases using innovative RNA interference strategies to improve treatment outcomes.
Genetically anchored drug target discovery for neglected diseases
GenDrug aims to develop innovative algorithms integrating genomic and real-world data to identify drug targets and accelerate drug development for neglected non-communicable diseases.
In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases
This project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively.
Harnessing a novel CRISPR nuclease for programmable counterselection in human cells
This project aims to enhance CRISPR genome editing efficiency by developing a programmable counter-selection mechanism to eliminate unedited cells, thereby reducing screening burdens in various applications.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
New Prime Editing and non-viral delivery strategies for Gene TherapyThis project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders. | EIC Pathfinder | € 4.406.097 | 2022 | Details |
A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing systemThe NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases. | EIC Pathfinder | € 2.988.377 | 2023 | Details |
TraffikGene-Tx: Targeted Peptide Carriers for RNA DeliveryTraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs. | EIC Transition | € 2.498.963 | 2023 | Details |
A novel bioinformatics SaaS platform to identify and classify the pathogenicity of single genomic variants and oligogenic variant combinations for the diagnosis and treatment of genetic diseaseseVai is a SaaS platform that enhances genetic variant interpretation, enabling accurate and rapid identification of pathogenic variants to improve diagnostic yields for genetic diseases. | EIC Accelerator | € 1.682.537 | 2022 | Details |
New Prime Editing and non-viral delivery strategies for Gene Therapy
This project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders.
A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system
The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.
TraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery
TraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs.
A novel bioinformatics SaaS platform to identify and classify the pathogenicity of single genomic variants and oligogenic variant combinations for the diagnosis and treatment of genetic diseases
eVai is a SaaS platform that enhances genetic variant interpretation, enabling accurate and rapid identification of pathogenic variants to improve diagnostic yields for genetic diseases.